138 related articles for article (PubMed ID: 38551221)
1. Nucleic acid vaccines-based therapy for triple-negative breast cancer: A new paradigm in tumor immunotherapy arena.
Saleh RO; Ibrahim FM; Pallathadka H; Kaur I; Ahmad I; Ali SHJ; Redhee AH; Ghildiyal P; Jawad MA; Alsaadi SB
Cell Biochem Funct; 2024 Apr; 42(3):e3992. PubMed ID: 38551221
[TBL] [Abstract][Full Text] [Related]
2. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
[TBL] [Abstract][Full Text] [Related]
3. Novel synthetic plasmid and Doggybone DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice.
Scott VL; Patel A; Villarreal DO; Hensley SE; Ragwan E; Yan J; Sardesai NY; Rothwell PJ; Extance JP; Caproni LJ; Weiner DB
Hum Vaccin Immunother; 2015; 11(8):1972-82. PubMed ID: 26091432
[TBL] [Abstract][Full Text] [Related]
4. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
5. Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer.
Pack CD; Bommireddy R; Munoz LE; Patel JM; Bozeman EN; Dey P; Radhakrishnan V; Vartabedian VF; Venkat K; Ramachandiran S; Reddy SJC; Selvaraj P
Hum Vaccin Immunother; 2020 Dec; 16(12):3184-3193. PubMed ID: 32530786
[TBL] [Abstract][Full Text] [Related]
6. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
7. Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer.
Niavarani SR; St-Cyr G; Daniel L; Lawson C; Giguère H; Alkayyal AA; Tai LH
Front Immunol; 2023; 14():1098344. PubMed ID: 36860852
[TBL] [Abstract][Full Text] [Related]
8. Helicase antigen (HAGE)-derived vaccines induce immunity to HAGE and ImmunoBody®-HAGE DNA vaccine delays the growth and metastasis of HAGE-expressing tumors in vivo.
Nagarajan D; Pearson J; Brentville V; Metheringham R; Pockley AG; Durrant L; McArdle SE
Immunol Cell Biol; 2021 Oct; 99(9):972-989. PubMed ID: 34105800
[TBL] [Abstract][Full Text] [Related]
9. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
Paret C; Simon P; Vormbrock K; Bender C; Kölsch A; Breitkreuz A; Yildiz Ö; Omokoko T; Hubich-Rau S; Hartmann C; Häcker S; Wagner M; Roldan DB; Selmi A; Türeci Ö; Sahin U
Oncotarget; 2015 Sep; 6(28):25356-67. PubMed ID: 26327325
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer.
Callmann CE; Cole LE; Kusmierz CD; Huang Z; Horiuchi D; Mirkin CA
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17543-17550. PubMed ID: 32669433
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
12. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic interventions of Triple Negative Breast Cancer.
Li Z; Qiu Y; Lu W; Jiang Y; Wang J
J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
[TBL] [Abstract][Full Text] [Related]
14. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.
Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C
Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
16. Recombinant hemagglutinin protein and DNA-RNA-combined nucleic acid vaccines harbored by yeast elicit protective immunity against H9N2 avian influenza infection.
Zhang H; Xie R; Zhang H; Sun R; Li S; Xia C; Li Z; Zhang L; Guo Y; Huang J
Poult Sci; 2023 Jun; 102(6):102662. PubMed ID: 37043959
[TBL] [Abstract][Full Text] [Related]
17. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
[TBL] [Abstract][Full Text] [Related]
18. Nucleic acid vaccines: A taboo broken and prospect for a hepatitis B virus cure.
Tsounis EP; Mouzaki A; Triantos C
World J Gastroenterol; 2021 Nov; 27(41):7005-7013. PubMed ID: 34887624
[TBL] [Abstract][Full Text] [Related]
19. NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses.
Ligtenberg MA; Rojas-Colonelli N; Kiessling R; Lladser A
Hum Vaccin Immunother; 2013 Oct; 9(10):2189-95. PubMed ID: 23884215
[TBL] [Abstract][Full Text] [Related]
20. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
